Our work built on these findings through a series of in vivo and in vitro experiments, showing that ARNTL2 is highly expressed in PCs and that its expression levels are inversely correlated with overall survival (OS) and disease-free survival (DFS) in pancreatic cancer patients. The gene discussed is BMAL2; the disease is familial pancreatic carcinoma.